A Multiple Dose Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ABT-288 in Stable Subjects With Schizophrenia

NCT00888693 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

81

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: ABT-288
DRUG: Placebo

Sponsor

AbbVie